15.30

2.00% 0.30

Myriad Genetics Inc (MYGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MYGN Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$15.00

Aprire:

$14.93

Volume 24 ore:

661.07K

Relative Volume:

0.88

Capitalizzazione di mercato:

$1.36B

Reddito:

$802.20M

Utile/perdita netta:

$-155.20M

Rapporto P/E:

-4.5536

EPS:

-3.36

Flusso di cassa netto:

$-141.30M

1 W Prestazione:

-3.04%

1M Prestazione:

-34.59%

6M Prestazione:

-38.82%

1 anno Prestazione:

-15.28%

Intervallo 1D:

$14.72

$15.33

Intervallo di 1 settimana:

$14.72

$16.07

Portata 52W:

$14.72

$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Nome

Myriad Genetics Inc

Settore

Healthcare (1193)

Industria

Diagnostics & Research (57)

Telefono

801-584-3600

Indirizzo

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Dipendente

2,700

Cinguettio

@myriadgenetics

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

MYGN's Discussions on Twitter

Confronta MYGN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MYGN	15.30	1.36B	802.20M	-155.20M	-141.30M	-3.36
TMO	512.84	195.55B	42.37B	6.14B	7.78B	15.26
DHR	233.10	166.92B	23.74B	3.89B	4.98B	7.93
A	128.57	36.94B	6.50B	1.41B	1.42B	3.82
IQV	194.38	35.03B	15.32B	1.41B	1.96B	5.95
IDXX	418.61	33.80B	3.84B	866.24M	792.60M	9.80

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-21	Ripresa	Piper Sandler	Neutral
2023-12-19	Iniziato	Wells Fargo	Equal Weight
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-07-05	Ripresa	JP Morgan	Underweight
2023-05-23	Aggiornamento	Goldman	Sell → Buy
2023-01-18	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-10-06	Iniziato	Stephens	Equal-Weight
2021-10-15	Ripresa	Cowen	Market Perform
2021-06-15	Iniziato	Raymond James	Mkt Perform
2021-06-03	Iniziato	Goldman	Sell
2019-09-26	Downgrade	BofA/Merrill	Neutral → Underperform
2019-08-14	Downgrade	Piper Jaffray	Overweight → Neutral
2019-08-02	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-08-01	Aggiornamento	Barclays	Underweight → Equal Weight
2019-07-29	Downgrade	Needham	Strong Buy → Hold
2019-07-09	Downgrade	Cowen	Outperform → Market Perform
2019-03-12	Reiterato	Needham	Strong Buy
2019-01-03	Iniziato	Needham	Strong Buy
2018-11-30	Aggiornamento	Goldman	Sell → Neutral
2018-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-07-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Iniziato	Goldman	Sell
2018-01-22	Reiterato	Barclays	Equal Weight
2018-01-05	Iniziato	BTIG Research	Buy
2017-10-02	Ripresa	Leerink Partners	Mkt Perform
2017-08-09	Reiterato	Barclays	Equal Weight
2017-02-08	Aggiornamento	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Iniziato	Deutsche Bank	Sell
2016-10-10	Downgrade	Ladenburg Thalmann	Neutral → Sell

Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

Nov 20, 2024

Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire

Nov 20, 2024

Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan

Nov 20, 2024

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN

Nov 20, 2024

Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat

Nov 20, 2024

Breast Cancer Screening and Diagnostic Techniques Market - openPR

Nov 20, 2024

Nov 19, 2024

Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst Downgrade - MarketBeat

Nov 19, 2024

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire

Nov 19, 2024

Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan

Nov 19, 2024

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance

Nov 19, 2024

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewswire Inc.

Nov 19, 2024

Nov 18, 2024

Morgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat

Nov 18, 2024

State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Nov 18, 2024

Nov 17, 2024

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire

Nov 17, 2024

Nov 15, 2024

Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire

Nov 14, 2024

Nov 13, 2024

Long Term Trading Analysis for (MYGN) - Stock Traders Daily

Nov 13, 2024

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times

Nov 13, 2024

Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR

Nov 13, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St

Nov 13, 2024

Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia

Nov 13, 2024

Nov 12, 2024